Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Intellia Therapeutics (NTLA)
NASDAQ:NTLA
RESEARCH TOOLSreports
Holding NTLA?
Track your performance easily
NTLA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.47 - $34.87
Previous Close$12.9
Volume2.13M
Average Volume (3M)2.47M
Market Cap
$1.31B
Enterprise Value$757.36M
Total Cash (Recent Filing)$658.11M
Total Debt (Recent Filing)$101.62M
Price to Earnings (P/E)―
Beta3.08
Next Earnings
Feb 20, 2025EPS Estimate
-$1.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.45
Shares Outstanding101,848,572
10 Day Avg. Volume2,133,428
30 Day Avg. Volume2,468,933
Standard Deviation0.24
R-Squared0.15
Alpha-0.00002
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)1.36
Price to Sales (P/S)30.49
Price to Cash Flow (P/CF)-3.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue17.58
Enterprise Value/Gross Profit20.88
Enterprise Value/Ebitda-1.53
Forecast
1Y Price Target
$51.53Price Target Upside285.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
Intellia Therapeutics News
PremiumCompany Announcements
Intellia Therapeutics Announces Promising CRISPR Therapy Results
Bulls Say, Bears Say
Bulls Say
Efficacy Of NTLA-2002NTLA-2002 led to 92% reduction in HAE attacks in Ph1 and met all efficacy.
Long-term Effectiveness Of Nex-zNex-z one-time treatment resulted in a significant reduction of serum TTR, which was durable to 24 months, indicating long-term effectiveness.
Safety And Tolerability Of Nex-zNex-z continues to appear well-tolerated with treatment-related liver enzyme elevations seen in 6% of ATTR-CM patients being mild and transient.
Bears Say
Competitive LandscapeGrowing competition in the transthyretin amyloidosis (ATTR) space has pressured the stock.
Efficacy ConcernsIn recent trials, the 6-minute walk distance declined by approximately 19-24 meters in the treated group, showing no meaningful difference compared to placebo.
Market AcceptanceGene editing theoretically offers a one and done 'functional cure;' however, its irreversible nature makes the bar for market acceptance high, especially considering that the long-term safety implications are not known.
---
Ownership Overview
1.74% Insiders
21.90% Mutual Funds
35.39% Other Institutional Investors
10.64% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NTLA FAQ
What was Intellia Therapeutics’s price range in the past 12 months?
Intellia Therapeutics lowest stock price was $12.47 and its highest was $34.87 in the past 12 months.
What is Intellia Therapeutics’s market cap?
Currently, no data Available
When is Intellia Therapeutics’s upcoming earnings report date?
Intellia Therapeutics’s upcoming earnings report date is Feb 20, 2025 which is in 56 days.
How were Intellia Therapeutics’s earnings last quarter?
Intellia Therapeutics released its earnings results on Nov 07, 2024. The company reported -$1.34 earnings per share for the quarter, beating the consensus estimate of -$1.39 by $0.05.
Is Intellia Therapeutics overvalued?
According to Wall Street analysts Intellia Therapeutics’s price is currently Undervalued.
Does Intellia Therapeutics pay dividends?
Intellia Therapeutics does not currently pay dividends.
What is Intellia Therapeutics’s EPS estimate?
Intellia Therapeutics’s EPS estimate is -$1.34.
How many shares outstanding does Intellia Therapeutics have?
Intellia Therapeutics has 101,848,570 shares outstanding.
What happened to Intellia Therapeutics’s price movement after its last earnings report?
Intellia Therapeutics reported an EPS of -$1.34 in its last earnings report, beating expectations of -$1.39. Following the earnings report the stock price went down -0.374%.
Which hedge fund is a major shareholder of Intellia Therapeutics?
Among the largest hedge funds holding Intellia Therapeutics’s share is ARK Investment Management LLC. It holds Intellia Therapeutics’s shares valued at 252M.
---
Intellia Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.53 (285.13% Upside)
$51.53 (285.13% Upside)
Blogger Sentiment
Bullish
NTLA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $38.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 5.2%
Last 30 Days ▲ 5.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.55%
12-Months-Change
Fundamentals
Return on Equity
-52.23%
Trailing 12-Months
Asset Growth
-5.63%
Trailing 12-Months
Company Description
Intellia Therapeutics
Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
---
NTLA Earnings Call
Q3 2024
0:00 / 0:00
---
NTLA Revenue Breakdown
100.00% Collaboration revenue
---
NTLA Stock 12 Month Forecast
Average Price Target
$51.53
▲(285.13% Upside)
Technical Analysis
Best Analysts Covering NTLA
1 Year
1 Year Success Rate
13/38 ratings generated profit
1 Year Average Return
+88.05%
reiterated a buy rating last month
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 34.21% of your transactions generating a profit, with an average return of +88.05% per trade.
---